Kalaris Therapeutics (KLRS) Misses Q3 EPS by 64c
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q3 EPS of ($0.64).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Melco Resorts & Entertainment (MLCO) Misses Q2 EPS by 7c
- High-Trend International Group reports BDI rise and revenue growth
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
